ConductScience.org, home

Paper32196896

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.

Kannt A and 16 others. Diabetes Obes Metab, 2020. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Papers, record 32196896. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32196896

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.
PubMed
Journal
Diabetes Obes Metab
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
1.63
iCite
Revised in PubMed
2021-06-24
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kannt AAimohttps://orcid.org/0000-0002-5197-2286
2Madsen ANAndreas Nygaard
3Kammermeier CClaire
4Elvert RRalfhttps://orcid.org/0000-0003-1216-307X
5Klöckener TTim
6Bossart MMartin
7Haack TTorsten
8Evers AAndreas
9Lorenz KKatrin
10Hennerici WWolfgang
11Rocher CCorinne
12Böcskei ZZsolt
13Guillemot JCJean-Claude
14Mikol VVincent
15Pattou FFrancois
16Staels BBart
17Wagner MMichael

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
IncretinsMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Animals
Glucagon-Like Peptide-1 Receptor
Mice
Mice, Inbred C57BL
Receptors, Glucagon

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
This work was supported by a grant from Agence Nationale pour la Recherche (ANR-16-RHUS-0006-PreciNASH).InternationalPubMed

Source PubMed

Download CSV of grants

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
41025003Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World J Gastroenterol2025https://conductscience.org/library/papers/41025003PubMed
39059360Transforming obesity: The advancement of multi-receptor drugs.Cell2024https://conductscience.org/library/papers/39059360PubMed
38978621Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/38978621PubMed
38818288Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.World J Hepatol2024https://conductscience.org/library/papers/38818288PubMed
38612640
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
Int J Mol Sci2024https://conductscience.org/library/papers/38612640PubMed
38486997Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis.Acta Pharm Sin B2024https://conductscience.org/library/papers/38486997PubMed
37823483Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases.Endocrinology2023https://conductscience.org/library/papers/37823483PubMed
37498367The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.Diabetologia2023https://conductscience.org/library/papers/37498367PubMed
37096236Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.J Diabetes Res2023https://conductscience.org/library/papers/37096236PubMed
36767008Pharmacological Support for the Treatment of Obesity-Present and Future.Healthcare (Basel)2023https://conductscience.org/library/papers/36767008PubMed
36675217GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.Int J Mol Sci2023https://conductscience.org/library/papers/36675217PubMed
35773269Targeting fibrosis, mechanisms and cilinical trials.Signal Transduct Target Ther2022https://conductscience.org/library/papers/35773269PubMed
34993389Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models.Curr Dev Nutr2021https://conductscience.org/library/papers/34993389PubMed
34934197GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.Acta Pharmacol Sin2022https://conductscience.org/library/papers/34934197PubMed
34805582Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.Transl Gastroenterol Hepatol2021https://conductscience.org/library/papers/34805582PubMed
34713962The incretin/glucagon system as a target for pharmacotherapy of obesity.Obes Rev2022https://conductscience.org/library/papers/34713962PubMed
34577569New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34577569PubMed
34068699Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?J Clin Med2021https://conductscience.org/library/papers/34068699PubMed
33948015Novel therapies with precision mechanisms for type 2 diabetes mellitus.Nat Rev Endocrinol2021https://conductscience.org/library/papers/33948015PubMed
33324348Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.Front Endocrinol (Lausanne)2020https://conductscience.org/library/papers/33324348PubMed

See all 21 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32196896

GET https://conductscience.org/api/papers/v1/32196896/cited_by?page=2